Trial Profile
A single-center, retrospective trial evaluating the effect of alemtuzumab compared to non-alemtuzumab-containing regimens in patients T-prolymphocytic leukemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Oct 2016
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Alemtuzumab (Primary) ; Antineoplastics
- Indications T-cell prolymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 22 Oct 2016 New trial record